A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Sanofi
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with involvement of at least 2 anatomical areas at screening and baseline
Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline
Patients with documented recent history (within 6 months before the screening visit) of inadequate response of atopic hand and foot dermatitis to topical medication(s)
Patients meet the diagnosis criteria for atopic dermatitis (AD)
Provide informed consent/assent signed by study patient or legally acceptable representative
Patients need to have been compliant with the skin protection measures through the entire duration of the screening period
You may not be if
Treatment with dupilumab in the past
Patients with a positive patch test reaction that are deemed to be clinically relevant as the current cause of the hand and foot dermatitis
Patients with documented exposure to irritants believed to be a predominant cause of the current hand and foot dermatitis
Treatment with systemic corticosteroids or non-steroidal immunosuppressive drugs within 4 weeks prior to baseline
Known history of HIV/HBV/HCV infection
Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the patient's participation in this study
Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment and during the study
Clareo Health | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
